In this episode of the ECTRIMS Podcast, recorded in collaboration with the Multiple Sclerosis Journal "Controversies in MS" series, host Prof. Anneke van der Walt moderates a discussion between Prof. Andy Solomon and Prof. Enrique Gómez on one of the most debated developments in modern multiple sclerosis diagnosis.

Together, they explore:

• Why misdiagnosis remains a major challenge in MS care
• The role of the central vein sign (CVS) and paramagnetic rim lesions (PRLs) in improving specificity
• Whether expanding diagnostic sensitivity may increase false positives
• The practical realities of implementing advanced MRI biomarkers globally
• The importance of radiology training, implementation science, and AI-assisted imaging
• How clinicians should approach MRI interpretation in real-world practice

This conversation examines the balance between earlier diagnosis, diagnostic accuracy, and equitable implementation of emerging diagnostic tools across different healthcare settings.

This episode is part of the MS Journal Controversies in MS series on The revised 2024 McDonald criteria can solve the misdiagnosis problem in MS. The accompanying Yes, No, and Commentary articles are available to read open access for the next month, compliments of MS Journal.

Epstein–Barr virus (EBV) has become one of the most intensely studied topics in multiple sclerosis research. But how strong is the evidence linking EBV to MS, and could targeting the virus change the future of treatment and prevention?

In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Gavin Giovannoni and Prof. Tomas Olsson about the evolving science connecting infections, immunity and multiple sclerosis.

Together, they explore:

• Molecular mimicry and how EBV proteins may trigger autoimmune responses
• Whether EBV contributes to chronic CNS inflammation and disease progression
• Emerging therapeutic approaches including antivirals, CAR-T cells, and vaccines

This conversation examines one of the most important scientific questions in MS research and the therapeutic possibilities that may emerge from it.

New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis.

In this exclusive episode, leading experts Prof. Ludwig Kappos from University of Basel and Dr. Jiwon Oh from Barlo MS Centre join host Brett Drummond to unpack the full FENhance 1 & 2 trial results.

Together, they explore:

• How fenebrutinib performed against teriflunomide in relapsing MS
• Why BTK inhibition continues to generate strong interest across the MS treatment landscape
• What the results reveal about relapse reduction, MRI outcomes, and disability progression
• What the safety profile of fenebrutinib looked like in this cohort of patients

Listen for a deep dive into the science, clinical context, and future implications for MS care.